IL13 and asthma: Similarly, the preventive activities of RosA in female BALB/c mice induced asthma demonstrated that pretreatment with RosA (5–20 mg/kg) 1 h prior to the OVA challenge significantly inhibited increases in Th2 cytokines (IL‐4, IL‐5, and IL‐13) and markedly reduced IgE concentrations in the BALF (Liang et al. 2016).